Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 28, 2011. The filing serves to announce the company's financial and operating results for the fiscal year ended December 31, 2010. The registrant is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. It solely references the issuance of a press release containing the year-end results. Any material changes would be described in the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer in accordance with General Instruction B.2 of Form 8-K. It states that the information in this report, including the press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, management commentary, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated March 28, 2011), as these numbers are absent from the 8-K body.
- Confirm the company name is PharmAthene, Inc., noting the discrepancy with the "Altimmune, Inc." label in the request metadata.
- Review the full press release for any forward-looking statements or operational updates regarding the company's drug development pipeline.
- Check subsequent filings for any updates to the financial condition reported for the year ended December 31, 2010.